RYTM(Rhythm Pharmaceuticals, Inc.) · 财务报表

RYTM(Rhythm Pharmaceuticals, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$3.15M$23.64M$77.43M$130.13M$189.76M
毛利润$2.56M$21.50M$68.13M$116.76M$170.26M
营业利润−$170.06M−$179.16M−$184.36M−$265.50M−$192.02M
净利润−$69.61M−$181.12M−$184.68M−$260.60M−$196.54M
经营现金流−$146.00M−$173.43M−$136.16M−$113.88M−$115.67M
自由现金流−$146.44M−$173.71M−$136.20M−$113.88M−$116.63M
摊薄每股收益$-1.40$-3.47$-3.20$-4.34$-3.11

Rhythm Pharmaceuticals, Inc. RYTM